Lumping and splitting: The need for precision medicine and "personomics" in endometrial cancer.
作者信息
Reyes-Baez Fiorella E, Garzon Simone, Mariani Andrea
机构信息
Department of Gynecology and Obstetrics, Mayo Clinic, Rochester, MN, USA.
出版信息
J Gynecol Oncol. 2021 Mar;32(2):e38. doi: 10.3802/jgo.2021.32.e38.
Abstract
摘要
相似文献
1
Lumping and splitting: The need for precision medicine and "personomics" in endometrial cancer.归并与细分：子宫内膜癌中精准医学和“个体组学”的必要性。
J Gynecol Oncol. 2021 Mar;32(2):e38. doi: 10.3802/jgo.2021.32.e38.
2
Molecular classification of endometrial cancer: entering an era of precision medicine.子宫内膜癌的分子分类：步入精准医学时代。
J Gynecol Oncol. 2022 May;33(3):e47. doi: 10.3802/jgo.2022.33.e47.
3
Precision medicine in endometrial cancer.
Gynecol Oncol. 2019 Sep;154(3):451-453. doi: 10.1016/j.ygyno.2019.08.001.
4
The problem of "lumping versus splitting".
Gynecol Oncol. 2005 Dec;99(3):527-9. doi: 10.1016/j.ygyno.2005.10.007. Epub 2005 Nov 2.
5
Summary of the 2013 American Association for Cancer Research (AACR) Annual Meeting.
Gynecol Oncol. 2013 Jul;130(1):6-8. doi: 10.1016/j.ygyno.2013.05.031.
6
Cancer genomics and clinical practice: how can we close the gap more quickly?癌症基因组学与临床实践：我们如何能更快缩小差距？
Curr Opin Obstet Gynecol. 2017 Feb;29(1):1-3. doi: 10.1097/GCO.0000000000000341.
7
Hsa-microRNA-181a is a regulator of a number of cancer genes and a biomarker for endometrial carcinoma in patients: a bioinformatic and clinical study and the therapeutic implication.人微小RNA-181a是多种癌症基因的调节因子及子宫内膜癌患者的生物标志物：一项生物信息学与临床研究及治疗意义
Drug Des Devel Ther. 2015 Feb 18;9:1103-75. doi: 10.2147/DDDT.S73551. eCollection 2015.
8
An miRNA signature associated with tumor mutation burden in endometrial cancer.与子宫内膜癌肿瘤突变负担相关的 miRNA 特征。
Biosci Rep. 2020 Nov 27;40(11). doi: 10.1042/BSR20203398.
9
Personomics and Precision Medicine.个人组学与精准医学。
Trans Am Clin Climatol Assoc. 2017;128:160-168.
10
Slow and steady wins the race: precision medicine for low risk endometrial cancer.
Int J Gynecol Cancer. 2020 Jun;30(6):724-725. doi: 10.1136/ijgc-2020-001467. Epub 2020 May 5.
引用本文的文献
1
Metastases and Recurrence Risk Factors in Endometrial Cancer-The Role of Selected Molecular Changes, Hormonal Factors, Diagnostic Methods and Surgery Procedures.子宫内膜癌的转移和复发风险因素——特定分子变化、激素因素、诊断方法及手术程序的作用
Cancers (Basel). 2023 Dec 29;16(1):179. doi: 10.3390/cancers16010179.
2
Conservative Management of Atypical Endometrial Hyperplasia and Early Endometrial Cancer in Childbearing Age Women.生育期妇女非典型子宫内膜增生和早期子宫内膜癌的保守管理。
Medicina (Kaunas). 2022 Sep 11;58(9):1256. doi: 10.3390/medicina58091256.
3
Ultrasound Measurement of Tumor-Free Distance from the Serosal Surface as the Alternative to Measuring the Depth of Myometrial Invasion in Predicting Lymph Node Metastases in Endometrial Cancer.超声测量距浆膜表面无肿瘤距离作为预测子宫内膜癌淋巴结转移时测量肌层浸润深度的替代方法
Diagnostics (Basel). 2021 Aug 14;11(8):1472. doi: 10.3390/diagnostics11081472.
本文引用的文献
1
Recurrence risk factors in stage IA grade 1 endometrial cancer.IA 期 G1 期子宫内膜癌的复发风险因素。
J Gynecol Oncol. 2021 Mar;32(2):e22. doi: 10.3802/jgo.2021.32.e22. Epub 2021 Jan 8.
2
Substantial lymph-vascular space invasion (LVSI) as predictor of distant relapse and poor prognosis in low-risk early-stage endometrial cancer.大量淋巴血管空间浸润（LVSI）可预测低危早期子宫内膜癌的远处复发和不良预后。
J Gynecol Oncol. 2021 Mar;32(2):e11. doi: 10.3802/jgo.2021.32.e11. Epub 2021 Jan 11.
3
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.ESGO/ESTRO/ESP 子宫内膜癌管理指南。
Int J Gynecol Cancer. 2021 Jan;31(1):12-39. doi: 10.1136/ijgc-2020-002230. Epub 2020 Dec 18.
4
Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy.分子分类时代的子宫内膜癌辅助治疗：放疗、放化疗和新的治疗靶点。
Int J Gynecol Cancer. 2021 Apr;31(4):594-604. doi: 10.1136/ijgc-2020-001822. Epub 2020 Oct 20.
5
PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer.PORTEC-4a：基于分子谱的辅助治疗用于中高危子宫内膜癌患者的国际随机试验。
Int J Gynecol Cancer. 2020 Dec;30(12):2002-2007. doi: 10.1136/ijgc-2020-001929. Epub 2020 Oct 12.
6
A Modern Approach to Endometrial Carcinoma: Will Molecular Classification Improve Precision Medicine in the Future?子宫内膜癌的现代治疗方法：分子分类未来会改善精准医学吗？
Cancers (Basel). 2020 Sep 10;12(9):2577. doi: 10.3390/cancers12092577.
7
Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy.PORTEC-3 试验高危子宫内膜癌的分子分类：对预后的影响和辅助治疗的获益。
J Clin Oncol. 2020 Oct 10;38(29):3388-3397. doi: 10.1200/JCO.20.00549. Epub 2020 Aug 4.
8
Precision Medicine Versus Evidence-Based Medicine: Individual Treatment Effect Versus Average Treatment Effect.精准医学与循证医学：个体治疗效果与平均治疗效果
Circulation. 2019 Oct 8;140(15):1236-1238. doi: 10.1161/CIRCULATIONAHA.119.043014. Epub 2019 Oct 7.
9
Lumpers and splitters: the bumpy road to precision medicine.概括者与细分者：精准医学的崎岖之路。
Eur Heart J. 2019 Oct 21;40(40):3292-3296. doi: 10.1093/eurheartj/ehz644.
10
The Precision of Evidence Needed to Practice "Precision Medicine".实施“精准医学”所需证据的精准性。
N Engl J Med. 2019 Jun 20;380(25):2472-2474. doi: 10.1056/NEJMe1906088. Epub 2019 Jun 3.
Zotero 插件